BioNTech stock jumped 22% on Wednesday to $113.12, marking its largest single-day gain since April 2023. The rally followed positive Phase 3 results from Moderna and Merck for their personalized cancer vaccine, a reminder that progress in oncology can move the broader vaccine group even when the underlying data do not involve every company in the sector.

The trial, known as INTerpath-001, showed that intismeran autogene combined with Merck’s Keytruda was more effective at preventing melanoma recurrence than Keytruda alone. The announcement sent Moderna shares to nearly triple, while Merck gained more than 12%.

BioNTech was not the only company to benefit from the news. Novavax rose 11% as vaccine stocks broadly advanced in response to the data.

Still, analysts at Leerink Partners quickly dampened enthusiasm around BNTX specifically. Analyst Daina Graybosch said the stock’s gains are likely “to fade as investors absorb the poor read-through.” In her view, the trial success belongs to Moderna and Merck, not BioNTech.

Although BioNTech has its own mRNA cancer vaccine program, it has lagged behind its rivals. The company’s cancer vaccine efforts are centered on its iNeST platform, developed with Roche’s Genentech unit. The platform is designed to target solid tumors through personalized, mutation-specific vaccines.

The pipeline has also faced setbacks. In late 2025, BioNTech paused development of its BNT111 candidate in advanced refractory melanoma after testing it with Regeneron’s Libtayo in a Phase 2 study.

Leerink now believes BioNTech’s chances of emerging as a leader in cancer vaccines have fallen to the point that this possibility is no longer reflected in the stock price, underscoring how investors are distinguishing between sector-wide enthusiasm and company-specific execution.

Goldman Sachs analyst Asad Haider recently highlighted BioNTech’s pumitamig as a more promising area, calling its non-small cell lung cancer data “encouraging,” although a rival drug is further ahead in development.

Beyond the pipeline, BioNTech is also navigating a leadership transition. Its husband-and-wife co-founders are expected to leave by year-end to launch a new company. BioNTech has agreed to license its mRNA technology to the new venture in exchange for a minority stake, milestone payments, and royalties.

The company is also under pressure financially. Second-quarter earnings showed BioNTech remains heavily reliant on declining Covid vaccine revenue, and its full-year revenue guidance came in below analyst expectations. By comparison, Pfizer, its Covid vaccine partner, has handled the post-pandemic transition more smoothly.

Analysts appear to be shifting focus away from BioNTech’s cancer vaccine program and toward other parts of its oncology portfolio.